<DOC>
	<DOCNO>NCT00910910</DOCNO>
	<brief_summary>The purpose study determine safety efficacy lenalidomide first line therapy treat patient B-cell Chronic Lymphocytic Leukemia . This study compare effect ( good bad ) lenalidomide chlorambucil .</brief_summary>
	<brief_title>Study Of The Effectiveness &amp; Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL ( The ORIGIN Trial )</brief_title>
	<detailed_description>After notification US Food Drug Administration ( FDA ) 12 July 2013 , Celgene agree discontinue lenalidomide treatment patient due imbalance number deaths patient treat lenalidomide versus patient treat chlorambucil . No specific causality imbalance identify date . Investigators instruct immediately discontinue participant experimental lenalidomide treatment inform patient accordingly . Participants Chlorambucil arm may continue 12 month ( 13 cycle ) last participant complete March 2014 . All randomize participant continue follow overall survival secondary primary malignancy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>1 . Must sign inform consent form . 2 . Age ≥ 65 year 3 . Must able adhere study visit schedule protocol requirement . 4 . Must document diagnosis Bcell CLL . 5 . Must Eastern Cooperative Oncology Group ( ECOG ) performance status score ≤2 . 6 . Must agree follow pregnancy precaution require protocol . 7 . Must agree receive counsel relate teratogenic risk lenalidomide . 8 . Must agree donate blood semen define protocol 1 . Prior treatment Bcell CLL . 2 . Any medical condition , would prevent subject signing informed consent form . 3 . Active infection require systemic antibiotic . 4 . Systemic infection resolve &gt; 2 month prior initiate lenalidomide 5 . Pregnant lactating female . 6 . Participation clinical study take investigational therapy within 28 day . 7 . Known presence alcohol and/or drug abuse . 8 . Central nervous system ( CNS ) involvement . 9 . Prior history malignancy , CLL , unless subject free disease ≥3 year . Exceptions include follow : Basal cell carcinoma skin Squamous cell carcinoma skin Carcinoma situ cervix Carcinoma situ breast Incidental histologic find prostate cancer ( TNM stage T1a T1b ) 10 . History renal failure require dialysis . 11 . Known Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) and/or Hepatitis C Virus ( HCV ) infection . 12 . Prior therapy lenalidomide . 13 . Evidence TLS screen 14 . Presence specific hematology and/or chemistry abnormality 15 . Uncontrolled hyperthyroidism hypothyroidism 16 . Venous thromboembolism within one year 17 . ≥ Grade2 neuropathy 18 . Uncontrolled autoimmune hemolytic anemia thrombocytopenia 19 . Disease transformation [ i.e . Richter 's Syndrome ( lymphoma ) prolymphocytic leukemia ]</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>